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Abstract
Background: Colorectal cancer (CRC) is the first cause of cancer deaths among Puerto Ricans. The incidence and
mortality of CRC in Puerto Rico continue to be on the rise. The burden of CRC in Puerto Rico is higher than among
US Hispanics and is second only to African Americans, thus supporting the importance of studying this CRC health
disparity. The genetic background of the Puerto Rican population is a mix of European, African, and Amerindian
races, which may account, in part, for the differences observed in the CRC mortality rates among Puerto Ricans. The
objective of the study was to assess the role of genetic ancestry in CRC risk and its association with
clinicopathological features of CRC tumors in Puerto Ricans.
Results: We used a validated panel of 105 ancestry informative markers (AIMs) to estimate genetic ancestry in 406
Puerto Rican CRC cases and 425 Puerto Rican controls. We examined the association of genetic ancestry with CRC
risk and tumor clinicopathological characteristics.
Conclusions: The mean ancestry proportions in the study population were 61% European, 21% African, and 18%
Amerindian. No association was observed between genetic ancestry and risk of CRC. However, African ancestry was
associated with an increased risk of developing rectal tumors (OR = 1.55, 95% CI 1.04–2.31). Additional studies are
needed to fully elucidate the role of African ancestry in CRC carcinogenesis.
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Introduction
Colorectal cancer (CRC) is the third most common
cancer diagnosed in the USA [1]. In Puerto Rico (PR),
CRC is the leading cause of cancer deaths, accounting
for 26.2%, when grouping men and women together
[2]. Data from the 2010 US Census determined that
Puerto Ricans are the second largest group of Latinos
in the USA, which represents approximately 9.0% of
the Latino population in the mainland [3]. Further-
more, due to the recent fiscal crisis in the island of PR,
it is expected that the number of Puerto Ricans in the
US mainland will continue to exponentially increase in
the next few years [4].
Compared to non-Hispanic Whites (NHW), Latinos in
general have lower CRC incidence rates [5, 6]. However,
when comparing CRC incidence rates across Latin
American countries, Puerto Ricans have higher CRC in-
cidence rates than Mexicans, Nicaraguans, Hondurans,
and most of the other Latin American countries [7]. In
the USA, Puerto Ricans living in Florida or California
have also been reported to have a higher incidence of
CRC than Mexicans living in these states [5, 8]. More-
over, in recent years, CRC incidence and mortality rates
among Puerto Ricans have been increasing. CRC mortal-
ity rates in Puerto Rico are higher than in US Latinos
and are only second to that of US non-Hispanic Blacks
(NHB) for reasons that remain unknown [1, 2].
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Several studies have shown that the genetic background
of the Latino subpopulations varies depending on the re-
gion of origin [9, 10]. As an admixed population, Puerto
Ricans have a genetic background comprised of varying
degrees of three ancestral populations: European, African,
and Amerindian (Taínos) [11–13]. Puerto Ricans have
higher levels of African genetic ancestry than what has
been described in most Latino subpopulations, and a
higher contribution of European ancestry when compared
to Mexicans [9, 10]. The variations observed in the genetic
background across Latino subpopulations reflect differ-
ences in the migration patterns of Europeans and Africans
into the Americas.
Previous studies have reported associations between
Amerindian and African genetic ancestry with an in-
creased risk of a variety of malignancies, including
melanoma, prostate, breast, and colorectal neoplasia
(adenomas and CRC) [14–18]. Most of the studies
examining the association between Amerindian genetic
ancestry and cancer have been focused on breast can-
cer. These studies have shown that US Latinas with
higher European ancestry and lower Amerindian ances-
try were more likely to develop breast cancer than
women with lower European and higher Amerindian
ancestry [19, 20]. Moreover, Amerindian ancestry has
been associated with worse breast cancer survival [21]
and an increased risk of recurrence of acute lympho-
blastic leukemia among children [22]. The role of
genetic ancestry in CRC risk among Puerto Ricans is
unknown. Given the heterogeneous genetic background
of this population, differences in genetic admixture may
partly explain the differences observed in the presenta-
tion and progression of CRC in the Puerto Rican popu-
lation. In this study, we present the findings of analyses
examining the association between genetic ancestry
with CRC risk and the clinicopathological features of
CRC tumors in the Puerto Rican population.
Results
Description of the study population
Cases and controls showed differences in age at re-
cruitment, gender, educational level, family history of
CRC, current drinker status, and ever smoked status
(Table 1). When compared to controls, individuals
with CRC were older (p < 0.001), more likely to be
male (p < 0.001), less educated (p < 0.001), and more
likely to not have family history of CRC (74.8% had no
family history vs. 67.3% in controls; p = 0.03) (Table 1).
Furthermore, CRC cases were less likely to drink
(78.1% were not drinkers; p < 0.001) and slightly more
likely to have ever smoked (61.9%, p = 0.02) than con-
trols (Table 1). The study participants did not signifi-
cantly differ in marital status (p = 0.50), type of health
insurance (p = 0.07), and BMI (p = 0.71) (Table 1).
Genetic ancestry and risk of CRC
The mean of each ancestral population (European,
African, and Amerindian) was calculated according to par-
ticipant status (Table 1). Controls had 61.0% European,
21.1% African, and 18.0% Amerindian mean ancestral
Table 1 Demographics and clinical characteristics by participant
status (n = 831)
Characteristic Control
(n = 425)
n (%)
CRC
(n = 406)
n (%)
p value**
Age at recruitment
< 60 years 293 (68.9) 198 (48.8) < 0.001
≥ 60 years 132 (31.1) 208 (51.2)
Gender
Male 120 (28.2) 211 (52.0) < 0.001
Female 305 (71.8) 195 (48.0)
Educational levela
≥ 12 years 155 (61.0) 123 (43.0) < 0.001
< 12 years 99 (39.0) 163 (57.0)
Marital statusa
Single/divorced/widowed 86 (35.4) 75 (32.5) 0.50
Married 157 (64.6) 156 (67.5)
Health insurancea
Private 119 (68.8) 184 (65.7) 0.07
Public 54 (31.2) 88 (31.4)
Other 0 (0.0) 8 (2.9)
Family history of CRCa
No 226 (67.3) 285 (74.8) 0.03
Yes 110 (32.7) 96 (25.2)
Current drinkera
No 263 (63.1) 286 (78.1) < 0.001
Yes 154 (36.9) 80 (21.9)
Ever smoked 100 cigarettes
No 290 (69.71) 228 (61.96) 0.02
Yes 126 (30.29) 140 (38.04)
BMIa
< 20 11 (2.7) 14 (3.6) 0.71
20–24 116 (28.2) 99 (25.1)
25–29 155 (37.7) 152 (38.6)
30 129 (31.4) 129 (32.7)
European ancestry
(mean ± SD)
0.610 ± 0.141 0.613 ± 0.122 0.82
African ancestry
(mean ± SD)
0.211 ± 0.131 0.207 ± 0.118 0.89
Amerindian ancestry
(mean ± SD)
0.180 ± 0.071 0.180 ± 0.071 0.63
**p value from chi-square distribution or Fisher’s exact test for categorical
variables and Mann-Whitney test for continuous variables
aCounts varied due to missing information
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proportions, whereas CRC cases had 61.3% European,
20.7% African, and 18.0% Amerindian (Table 1). No sta-
tistically significant differences were observed in the
distribution of ancestry proportions between cases and
controls. A visual representation of the ancestry pro-
portions by participant status is shown in Fig. 1. As
seen in Fig. 1, the proportion of ancestral populations
in controls and CRC cases has a similar distribution
across the two study groups. When considering genetic
ancestry as dichotomous variables, we used a cut-off of
the median value of each ancestral population among
controls (equal or less than mean vs. more than mean
ancestry). However, we did not find evidence of an as-
sociation between genetic ancestry and CRC risk
(Table 2). Genetic ancestry was also analyzed using
tertiles and quartiles, but no statistically significant
findings were found (data not shown). In addition, gen-
etic ancestry was evaluated using a categorical variable
based on quartiles and treated as a continuous variable
to determine the variation in risk per 25% increase in
the ancestry of each ancestral population, and no statis-
tically significant findings were observed (Table 2). Fur-
thermore, genetic ancestry was evaluated as stratified
by age at recruitment (< 60 years and ≥ 60 years) and
found no statistically significant changes in the contri-
bution of genetic ancestry by age at recruitment to the
development of CRC (Table 3).
Genetic ancestry and CRC tumor characteristics
The pathological and molecular characteristics of CRC tu-
mors was evaluated by each ancestral population and pre-
sented in Tables 4 and 5. These tumor characteristics are
important to evaluate since CRC subtypes arise through
different mechanisms. Furthermore, understanding the
contribution of genetic ancestry to these CRC subtypes
might increase our knowledge of the biological and mo-
lecular pathways that lead to CRC development in
Hispanics. The pathological characteristics evaluated in
our study included tumor location, tumor stage, and
tumor differentiation. As seen in Table 4, individuals with
high Amerindian ancestry were more likely to have tu-
mors located in the distal colon (Table 4). However, after
adjustments for confounders tumor location was not sig-
nificantly associated with Amerindian ancestry (Table 5).
Moreover, after adjustment for age at recruitment, gender,
education, family history, ever smoked status, and current
drinking status, individuals with higher levels of African
ancestry were three times more likely to present with
CRC tumors located in the rectum (OR = 1.55, 95% CI
1.04–2.31) compared to those with low levels of African
ancestry (Table 5). No significant associations were found
between any of the tumor characteristics, and European
or Amerindian ancestry (Tables 4 and 5), even when ana-
lyzing genetic ancestry using tertiles and quartiles (data
not shown). Additionally, molecular tumor characteristics,
such as microsatellite instability, CpG island methylator
phenotype (CIMP), and mutations in KRAS and BRAF,
were evaluated in our CRC study population. These mo-
lecular markers are associated with different CRC sub-
types and are used for the clinical management of CRC
[23–28]; thus, it is important to understand if genetic an-
cestry is associated with these molecular markers. As de-
scribed in Table 4, KRAS-mutated tumors were more
frequently found on patients with low Amerindian
Fig. 1 Proportion of ancestral populations by CRC status. Our study populations were divided into controls and CRC cases, and ancestral
population proportions were graphed. Each line represents an individual. African ancestry proportions are shown in red, European ancestry
proportions are shown in blue, and Amerindian or Taíno ancestry proportions are shown in green
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ancestry (Table 4). However, after adjustments for con-
founders, none of the ancestral populations were associ-
ated with any of the somatic molecular markers studied.
Discussion
Our results showed that differences in the proportion
of ancestral populations were not associated with CRC
risk in Puerto Rican Latinos. Previous studies have
shown associations between differences in the genetic
ancestry of an individual with a variety of cancers in-
cluding breast, melanoma, and prostate [15, 21, 29–34].
To our knowledge, only one other study has examined
the association of genetic ancestry with CRC in a
Latino population [14]. Hernandez-Suarez et al. studied
a population of Colombians and found an increased
risk for development of colorectal polyps and CRC per
10% increase in African ancestry [14]. The differences
observed between the results for Colombians and our
study population could not only be attributed to differ-
ences in other risk factors, but also in variations in the
percentage of the contribution of the ancestral popula-
tions to the genetic background of the population. As
Table 2 Association of genetic ancestry with CRC status
Ancestry CRC
ORunadjusted ORadjusted
b ORadjusted
c
Categorical variablea
European ancestry
≤ (0.63) 1.0 1.0 1.0
> (0.63) 0.95 (0.73–1.25) 0.92 (0.61–1.39) 0.98 (0.64–1.50)
African ancestry
≤ (0.18) 1.0 1.0 1.0
> (0.18) 1.08 (0.82–1.41) 1.12 (0.74–1.68) 1.16 (0.76–1.76)
Amerindian ancestry
≤ (0.17) 1.0 1.0 1.0
> (0.17) 1.19 (0.91–1.57) 1.03 (0.68–1.54) 0.99 (0.65–1.50)
Continuous variabled
European ancestry 0.98 (0.87–1.11) 1.01 (0.84–1.22) 1.04 (0.86–1.26)
African ancestry 1.01 (0.89–1.14) 1.01 (0.84–1.21) 1.01 (0.84–1.22)
Amerindian ancestry 1.04 (0.63–1.22) 0.92 (0.77–1.11) 0.89 (0.74–1.08)
aDichotomous variables were analyzed using the median value of each ancestry marker among controls as a cut-off
bPOR’s adjusted by age at recruitment, gender, education, and family history of CRC
cPOR’s adjusted by age at recruitment, gender, education, and family history of CRC, ever smoked, and current drinking
dCategorical variables were categorized into quartiles and treated as continuous variables to measure the variation in risk per 25% increase of each
ancestry marker
Table 3 Association of genetic ancestry (categorical variable)a with CRC status by age at recruitment
Ancestry OR< 60 years OR≥ 60 years
ORunadjusted ORadjusted
b ORadjusted
c ORunadjusted ORadjusted
b ORadjusted
c
European ancestry
≤ (0.63) 1.0 1.0
> (0.63) 0.91 (0.63–1.31) 0.85 (0.49–1.48) 0.94 (0.53–1.67) 0.95 (0.62–1.47) 0.95 (0.51–1.78) 0.97 (0.51–1.86)
African ancestry
≤ (0.18) 1.0 1.0
> (0.18) 1.14 (0.79–1.63) 1.11 (0.64–1.92) 1.07 (0.60–1.91) 1.18 (0.76–1.83) 1.25 (0.67–2.35) 1.32 (0.70–2.52)
Amerindian ancestry
≤ (0.17) 1.0 1.0
> (0.17) 1.35 (0.94–1.94) 1.39 (0.79–2.43) 1.31 (0.73–2.34) 1.00 (0.65–1.55) 0.76 (0.41–1.40) 0.75 (0.40–1.40)
aDichotomous variables were analyzed using the median value of each ancestry marker among controls as a cut-off
bPOR’s adjusted by age at recruitment, gender, education, and family history of CRC
cPOR’s adjusted by age at recruitment, gender, education, and family history of CRC, ever smoked, and current drinking
dCategorical variables were categorized into quartiles and treated as continuous variables to measure the variation in risk per 25% increase of each
ancestry marker
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shown in the study by Hernandez-Suarez et al.,
Colombians have lower levels of European (38–44%)
and African ancestry (11–13%) than Puerto Ricans
(European 60–61%; African 19–21%). Additionally, the
percentage of Amerindian ancestry in the Colombian
population is much higher (39–45%) than in Puerto
Ricans (18%). The variations observed in the percentage
of each of these ancestral populations in the genetic back-
ground may perhaps contribute to the observed discrep-
ancies on the risk of CRC in each Latino subpopulation.
However, variations in the genetic ancestral background
may interact with other genetic alterations, environmental
exposures, and/or dietary patterns, thereby modulating
CRC risk.
Our study also evaluated the association of genetic an-
cestry with CRC tumor pathological and molecular char-
acteristics. Our results showed that African ancestry
increases the odds of having rectal tumors (Table 4). This
finding is in contrast with the reported literature that has
consistently found an increase in the diagnosis of proximal
location of colorectal tumors in African American and
Latino patients [35–39]. The localization of colorectal tu-
mors is important since proximal tumors are more likely
to be missed during screening colonoscopy [40] and are
associated with worse prognosis [38]. In addition, rectal
tumors are treated with radiation therapy, which is not
generally recommended for proximal tumors [41]. How-
ever, comprehensive molecular analyses using data from
The Cancer Genome Atlas (TCGA) showed that proximal
and distal (rectal) tumors were not significantly different
[42]. Therefore, further analyses of the particular genetic
pathways present among Puerto Rican and their associ-
ation with the African ancestry-specific loci are needed to
examine the role of African Ancestry and tumor location.
Table 4 Distribution of tumor characteristics by ancestral population among patients with CRC
European ancestrya African ancestrya Amerindian ancestrya
Tumor characteristic ≤ 0.63
n (%)
> 0.63
n (%)
p value* ≤ 0.18
n (%)
> 0.18
n (%)
p value* ≤ 0.17
n (%)
> 0.17
n (%)
p value*
Tumor location (n = 336)
Proximal 40 (22.22) 32 (20.51) 0.53 40 (25.64) 32 (17.78) 0.11 29 (19.85) 43 (23.50) 0.03
Distal 39 (21.67) 42 (26.92) 40 (25.64) 41 (22.78) 29 (18.95) 52 (28.42)
Rectum 101 (56.11) 82 (52.56) 76 (48.72) 107 (59.44) 95 (62.09) 88 (48.09)
Tumor stage (n = 266)
0/ I/II 70 (51.09) 59 (45.74) 0.55 60 (46.51) 69 (50.36) 0.74 55 (49.55) 74 (47.74) 0.89
III/IV 53 (38.69) 52 (40.31) 54 (41.86) 51 (37.23) 42 (37.84) 63 (40.65)
Other/unknown 14 (10.22) 18 (13.95) 15 (11.63) 17 (12.41) 14 (12.61) 18 (11.61)
Tumor differentiation
(n = 250)
High 27 (20.77) 31 (25.83) 0.34 33 (27.05) 25 (19.53) 0.16 24 (22.43) 34 (23.78) 0.80
Low/moderate 103 (79.23) 89 (74.17) 89 (72.95) 103 (80.47) 83 (77.57) 109 (76.22)
Microsatellite status
(n = 108)
Stable 51 (98.08) 52 (92.86) 0.37 51 (92.73) 52 (98.11) 0.36 47 (95.92) 56 (94.92) 0.99
Low/high 1 (1.92) 4 (7.14) 4 (7.27) 1 (1.89) 2 (4.08) 3 (5.08)
CIMP status (n = 83)
Absent 6 (12.50) 3 (8.57) 0.73 2 (6.06) 7 (14.00) 0.31 6 (13.04) 3 (8.11) 0.73
Low 42 (87.50) 32 (91.43) 31 (93.94) 43 (86.00) 40 (86.96) 34 (91.89)
KRAS mutation status
(n = 109)
Wild type 35 (64.81) 39 (70.91) 0.50 37 (69.81) 37 (66.07) 0.68 31 (57.41) 43 (78.18) 0.02
Mutated 19 (35.19) 16 (29.09) 16 (30.19) 19 (33.93) 23 (42.59) 12 (21.82)
BRAF mutation status
(n = 106)
Wild type 51 (96.23) 47 (88.68) 0.27 49 (96.08) 49 (89.09) 0.27 49 (89.09) 49 (96.08) 0.27
Mutated 2 (3.77) 6 (11.32) 2 (3.92) 6 (10.91) 6 (10.91) 2 (3.92)
*p value from chi-square or Fisher’s exact test
aDichotomous variables were analyzed the median value of each ancestry marker among controls as a cut-off
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There are several limitations in our study that need
to be addressed and considered. First, we did not per-
form analyses of locus-specific ancestry. This type of
analysis could aid in pinpointing the underlying causes
of the association of African ancestry with a rectal lo-
cation in our study population. A second limitation to
consider is that not all of the CRC tumors had mo-
lecular characteristics data (MSI, CIMP, KRAS, BRAF)
available, and this could potentially affect the statis-
tical power of our analysis to detect differences. Add-
itionally, we did not collect information on annual
income for our study participants. It has been shown
that socioeconomic status correlates with genetic an-
cestry [43]. However, we did collect information on
educational level, which have been shown they could
be used as a proxy for evaluating the effect of socio-
economic status [44–46]. In our study population, the
health insurance status was similar across cases and
controls. However, educational levels were higher
among controls compared to CRC cases. Hence, our
final statistical model for the association of ancestry
with CRC was adjusted for educational level as well as
other relevant socio-demographic factors. CRC cases
had a higher number of males, which resembles the
population of individuals with CRC in PR where men
are more likely to be diagnosed with CRC as compared
to women and are diagnosed with CRC > 60 years old
[2]. In addition, CRC cases were older than controls,
which is comparable to what has been found in other
genetic studies [47–50]. Furthermore, adjustment for
age in our statistical analyses did not change estimates
by more than 15% suggesting that age is not a con-
founder. Our study controls were shown to have a
greater proportion of self-reported family history
(non-hereditary) as compared to cases. This might be
explained by controls being motivated to seek screen-
ing colonoscopies due to cancer history on their fam-
ilies, whereas those that ended up being cases were
more likely motivated by symptoms brought on before
the diagnosis of CRC [51, 52].
Table 5 Association of tumors characteristics with ancestral markers among patients with CRC
European ancestrya African ancestrya Amerindian ancestrya
Tumor characteristicb OR unadjusted
(95% CI)
OR adjustedc
(95% CI)
OR unadjusted (95% CI) OR adjustedc
(95% CI)
OR unadjusted (95% CI) OR adjustedc
(95% CI)
Tumor location
Proximal 0.84 (0.51–1.39) 0.91 (0.53–1.58) 0.80 (0.48–1.31) 0.83 (0.48–1.45) 1.39 (0.84–2.32) 1.27 (0.73–2.23)
Distal 1.13 (0.70–1.82) 1.13 (0.66–1.91) 1.02 (0.63–1.64) 1.37 (0.80–2.35) 1.69 (1.03–2.75) 1.32 (0.78–2.26)
Rectum 0.85 (0.60–1.21) 0.88 (0.60–1.31) 1.40 (0.98–1.99) 1.55 (1.05–2.31) 0.87 (0.62–1.23) 0.75 (0.51–1.11)
Tumor stage
0/I/II 0.89 (0.60–1.32) 0.88 (0.56–1.38) 1.14 (0.77–1.70) 1.43 (0.91–2.25) 1.28 (0.86–1.90) 1.04 (0.66–1.63)
III/IV 1.03 (0.67–1.58) 1.15 (0.72–1.83) 0.94 (0.61–1.4) 0.93 (0.58–1.48) 1.42 (0.92–2.20) 1.34 (0.83–2.14)
Other/unknown 1.35 (0.66–2.79) 1.53 (0.72–3.23) 1.13 (0.55–2.32) 1.07 (0.51–2.26) 1.22 (0.59–2.52) 1.06 (0.50–2.22)
Tumor differentiation
High 1.21 (0.70–2.10) 1.25 (0.68–2.29) 0.75 (0.43–1.31) 0.90 (0.49–1.66) 1.35 (0.77–2.35) 1.16 (0.63–2.14)
Moderate/low 0.91 (0.65–1.28) 0.95 (0.64–1.39) 1.15 (0.82–1.62) 1.20 (0.82–1.77) 1.25 (0.88–1.76) 1.11 (0.75–1.63)
Microsatellite status
Stable 1.08 (0.70–1.66) 1.02 (0.63–1.65) 1.01 (0.66–1.55) 1.23 (0.76–2.00) 1.14 (0.74–1.75) 1.08 (0.67–1.75)
Low/high 4.23 (0.47–38.19) 4.38 (0.48–36.62) 0.25 (0.03–2.23) 0.52 (0.03–2.25) 1.43 (0.24–8.65) 1.39 (0.23–8.46)
CIMP status
None 0.53 (0.13–2.14) 0.57 (0.14–2.33) 3.47 (0.71–16.88) 3.72 (0.74–18.72) 0.48 (0.12–1.93) 0.42 (0.10–1.74)
Low 0.81 (0.49–1.33) 0.85 (0.49–1.47) 1.37 (0.83–2.26) 1.50 (0.86–2.60) 0.81 (0.49–1.33) 0.83 (0.48–1.44)
KRAS mutation status
Wild type 1.18 (0.72–1.93) 1.23 (0.72–2.10) 0.99 (0.60–1.62) 1.11 (0.65–1.90) 1.31 (0.80–2.16) 1.20 (0.70–2.07)
Mutated 0.89 (0.45–1.78) 0.86 (0.42–1.75) 1.18 (0.60–2.35) 1.17 (0.57–2.40) 0.49 (0.24–1.02) 0.49 (0.23–1.02)
BRAF mutation status
Wild type 0.98 (0.63–1.51) 1.01 (0.62–1.63) 0.99 (0.64–1.54) 1.02 (0.63–1.65) 0.94 (0.61–1.47) 0.92 (0.57–1.49)
Mutated 3.17 (0.63–15.91) 2.68 (0.51–14.10) 2.97 (0.59–14.89) 6.36 (0.74–54.37) 0.31 (0.06–1.58) 0.13 (0.02–1.13)
aDichotomous variables were analyzed the median value of each ancestry marker among controls as a cut-off
bControls as reference category
cPOR’s adjusted by age at recruitment, gender, ever smoked, current drinking, and BMI
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As this is a case-control study, it may occur that some ex-
posures are reported lower in cases than in controls, in part
due to changes in habits (due to the development of symp-
toms) leading up to a diagnosis. Our control group showed
a higher consumption of alcohol than our cases. However,
the consumption rate was found to be similar to what has
been reported in a national study (Puerto Rico Behavioral
Risk Factor Screening and Surveillance System) [53]. Puerto
Rico Behavioral Risk Factor Surveillance System (BRFSS) is
a state-based system of health surveys established in 1984
by the Centers for Disease Control to collect information
on health risk behaviors, preventive health practices, and
health care access primarily related to chronic disease and
injury [53]. Reported exposures on smoking, BMI, and alco-
hol consumption were similar between the study controls
and the PR BRFSS, which supports that our controls are
similar to the population of PR. Furthermore, the data col-
lected for alcohol exposure is the current consumption and
may reflect changes in the alcohol consumption habits of
patients diagnosed with cancer.
We acknowledge that there might be other genetic
causes for the development of CRC, not examined in the
current investigation. The focus of this study was sporadic
(non-hereditary) CRC, thus, we excluded hereditary colo-
rectal cancer cases since their increased risk for CRC de-
velopment is due to germline mutations in a variety of
cancer predisposing genes. Our group has published arti-
cles describing the clinical characteristics and mutational
spectrum of these hereditary colorectal syndromes in PR
[54–56]. Moreover, it is possible that common variants in
these cancer predisposing genes increase CRC risk in the
PR population. Additional studies to investigate common
variants in those genes might be needed to clarify their
role in sporadic CRC development.
Our study has several features that strengthen our
findings. This is the first report to describe the role of
genetic ancestry in the development of CRC in Puerto
Rican Latinos, one of the largest groups of Hispanics in
mainland US. To the best of our knowledge, this is the
first study of CRC in Latinos to include pathological
and molecular tumor characteristics in association with
genetic ancestry estimations. All of the CRC cases in-
cluded in the study were pathology-confirmed. Path-
ology data was obtained from the Puerto Rico Central
Cancer Registry (PRCCR) (http://www.salud.gov.pr/
Estadisticas-Registros-y-Publicaciones/Pages/Registros/
Registro-de-C%C3%A1ncer.aspx) and included all
tumor characteristics, such as tumor location, differen-
tiation, and staging. However, the PRCCR does not collect
any racial or genetic ancestry data. Thus, this is the first re-
port to show that genetic ancestry was associated with a
colorectal tumor characteristic in Latinos and shows the
importance of understanding the genetic background in re-
lation to cancer risk. Our results provide additional data on
the potential role of African ancestry in specific CRC
phenotype and warrant additional studies focused on un-
derstanding the mechanisms by which ancestry influences
CRC tumor characteristics using techniques, such as ad-
mixture mapping. This technique could help pinpoint the
genes involved in the observed association and examined
additional locus that may increase CRC risk.
Conclusions
This is the first report to comprehensively examine the as-
sociation of genetic ancestry with CRC among Puerto
Ricans a subpopulation of US Hispanics with a high risk for
CRC compared to other Latino subgroups. There was no
association between genetic ancestry and risk of CRC devel-
opment. However, our results showed that African ancestry
was associated with rectal tumor location in the Puerto
Rican population, which can have an impact on screening
and treatment options for patients. Additional studies to
elucidate the role of African ancestry in the development of
rectal tumors in the Puerto Rican population are needed.
Materials and methods
Study population
Participants in this study were recruited through the
Puerto Rico Familial Colorectal Cancer Registry (PURIFI-
CAR; http://purificar.rcm.upr.edu), a clinic-based registry
of CRC patients in the island that started in 2007. The
registry includes individuals with and without cancer with
ages ranging from 21 to 85 years old. Cases have
pathology-confirmed CRC, and controls are individuals
with no previous history of colorectal neoplasia (polyps
and/or CRC) who underwent a CRC screening colonos-
copy and no polyps and/or cancer were detected. Both
cases and controls are recruited into PURIFICAR through
gastroenterology and surgery clinics at the University of
Puerto Rico Comprehensive Cancer Center, University of
Puerto Rico Medical Center, the Isaac Gonzalez Martinez
Oncologic Hospital, the Ashford Presbyterian Hospital,
and those referred to PURIFICAR by gastroenterologists/
surgeons from across the island of PR. Eligibility criteria
for this study included being 21 years of age or older, cases
having pathology-confirmed CRC, and controls having a
negative colonoscopy and no previous history of colorectal
neoplasia. Individuals (both cases and controls) with
self-reported family history of CRC, not related to a her-
editary syndrome, were also included. For this study, fam-
ily history of CRC was defined as self-reported history of
CRC in first-, second-, or third-degree relatives. However,
cases with hereditary colorectal cancer syndromes as iden-
tified by germline genetic testing were excluded, since the
increased risk of CRC on these individuals is due to an
inherited mutation in cancer predisposing genes. Our
group has previously described the mutational spectrum
and clinical characteristics of the hereditary colorectal
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cancer in PR [54, 55]. Participants diagnosed with colorec-
tal polyps and other non-colorectal cancers were also ex-
cluded. Informed consent was obtained for all individuals
that participated in the study. The protocol was approved
by the University of Puerto Rico Medical Sciences Campus
Institutional Review Board.
Data collection
Risk factor and diet questionnaire
All participants completed a questionnaire (in Spanish)
modeled by the one used in the Collaborative Family
Registries for Colorectal Cancer (Colon CFR) [57]. This
questionnaire covers information regarding medical his-
tory, reproductive history, diet, physical activity, lifestyle
factors, and demographic information. Furthermore, a de-
tailed family history of cancer was obtained for each sub-
ject. Certified personnel conducted the informed consent
and interviews at the Puerto Rico Consortium for Clinical
and Translational Research (https://prctrc.rcm.upr.edu).
Pathology and clinical data
Pathology reports were obtained for all cases from the
PR Central Cancer Registry (http://www.salud.gov.pr/
Estadisticas-Registros-y-Publicaciones/Pages/Registros/
Registro-de-C%C3%A1ncer.aspx) or medical records,
which were obtained for all study participants. Data on
tumor location, tumor stage (TNM stage, tumor differ-
entiation, lymph node metastasis), and number of posi-
tive lymph nodes were collected.
Genomic DNA extraction and quality control
Blood samples were collected from study participants ac-
cording to standard operating procedures. Lymphocytes
were isolated from whole blood using Ficoll density gra-
dient centrifugation, and genomic DNA was extracted
from peripheral blood lymphocytes (PBLs) using Qiagen
Gentra DNA Puregene Kit (Qiagen) following the proto-
col provided by the manufacturers. DNA was quantified
by spectrophotometry at an absorbance of 260 nm. The
purity of DNA was estimated using the 260/280 ratios.
Colorectal tumor molecular analysis
For CRC cases, microsatellite instability analysis (commer-
cial testing) was obtained from pathology reports when
available. Microsatellite instability analysis consists of ana-
lyzing a set of genetic markers in normal mucosa and
tumor tissue [58, 59]. If the number of repeats differs in
tumor tissue and mucosa, then the tumor is classified as
having microsatellite instability. KRAS/BRAF mutational
status (tumor DNA sequencing) was obtained from path-
ology reports when information was available. For a subset
of CRC cases, CpG island methylation phenotype (CIMP)
was performed. Briefly, CIMP analysis consists of analyz-
ing the methylation status of the CpG island in the
following genes CAGNA1G, CRABP1, NEUROG1, IGF2,
RUNX3, SOCS1, CDKN2, and MLH1 [24, 60, 61] using
specific primers. DNA is extracted from CRC tumors and
bisulfite modified using the methylSEQr Kit (Applied
Biosystems) following the manufacturer’s protocol. The
bisulfite-modified DNA was used for the subsequent
methylation-specific PCR (MSP). Tumors were classified
according to CIMP status as follows: CIMP-Zero (0 meth-
ylated genes), CIMP-Low (1 to 5 methylated genes), and
CIMP-High (6 to 8 methylated genes) [25].
AIMS panel genotyping
Genomic DNA extracted from PBLs was used to geno-
type 105 AIMs panel using the Sequenom MassArray
iPLEX platform following the manufacturer’s recom-
mendations. The AIMs panel consists of carefully se-
lected SNP markers that were informative for ancestry
between three ancestral populations (European, African,
and Amerindian) [62, 63]. This AIMs panel was validated
for estimating continental ancestry information in a var-
iety of admixed populations, including Puerto Ricans [62,
63]. Genotype SNP calls were generated using the Seque-
nom TYPER software, which calls allele-specific peaks ac-
cording to their masses. Genotyping quality control for all
SNPs assessed included (1) using blinded duplicate geno-
typing for 60 DNA samples; (2) a genotype concordance
rate of 99% for all markers; and (3) genotyping call rates
exceeding 98.5% in all individuals genotyped.
Inference of ancestry proportions
The STRUCTURE v2.3 software was used to calculate
individual ancestry estimates for each participant
using a model-based clustering method implemented
in the program [64]. Parental population genotypes
from Africans, Europeans, and Amerindians were used
to determine ancestry estimates under the admixture
model as previously described [62, 63], using the
Bayesian Markov chain Monte Carlo method (K = 3;
assumes 3 founding populations) and a burn-in length
of 30,000 for 70,000 repetitions.
Statistical analysis
In this study, we included 1000 subjects recruited into the
PURIFICAR, of which 169 did not pass genotyping quality
controls, and were excluded. A total of 425 controls and
406 CRC cases, which passed genotyping quality control
analysis, were available for this study. Socio-demographic
and clinical characteristics were evaluated according to
participant status. The socio-demographic variables evalu-
ated in the study included gender, marital status (single/
divorced/widowed and married), educational level (< 12
years and ≥ 12 years), type of health insurance (private and
public and other), family history of CRC (first- and/or
second-degree relatives with CRC and none), current
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drinker (no and yes), ever smoked 100 cigarettes during
their life (no and yes), and BMI (underweight/normal and
overweight/obese). In addition, the following clinicopatho-
logical variables and tumor characteristics were evaluated:
age at cancer diagnosis, tumor location (proximal, distal
and rectum), tumor stage (0/I/II, III/IV, and other/un-
known), tumor differentiation (high and low/moderate),
KRAS/BRAF mutation status (wild type and mutated),
MSI status (high and stable) and CIMP status (0 and low).
Genetic ancestry was modeled both as a continuous vari-
able (% of European, African, and Amerindian ancestry)
and as a categorical variable (dichotomous for each ances-
tral population: less or equal than mean ancestry levels
and more than mean ancestry levels), also tertiles and
quartiles for each estimated ancestral population (0–25%,
26–50%, 51%–75%, and 76%–100%) were used as categor-
ical variables.
Sociodemographic and clinicopathological characteris-
tics were evaluated according to CRC status using Pear-
son’s chi-square or Fisher’s exact test, as appropriate for
categorical variables, and Mann-Whitney test for continu-
ous variables. Overall, European and African ancestry
were highly inversely correlated (R = − 0.84), whereas
European and Amerindian (R = − 0.37), and African and
Amerindian (R = − 0.18) were less correlated. Therefore,
we considered models that mutually adjusted African and
European by Amerindian ancestry. Overall, we found that
ORs did not differ by more than 5% in models with both
ancestral populations; thus, we present models with single
ancestral populations. Logistic regression models were fit-
ted to estimate the unadjusted and adjusted odds ratio
(OR) and its 95% confidence interval (CI) for the associ-
ation of CRC status and ancestry, considering the follow-
ing covariates: age at recruitment, gender, education,
family history of CRC, ever smoked, and current drinking.
Unadjusted and adjusted ORs did not differ by more than
15% between models for each ancestral population; there-
fore, we present unadjusted ORs. Among CRC cases, the
comparison of tumor characteristics according to the me-
dian of ancestry markers among controls was evaluated
using Pearson’s chi-square or Fisher’s exact test, as appro-
priate. Polytomous regression models were fitted to esti-
mate the unadjusted and adjusted odds ratio (OR) and its
95% confidence interval (CI) for the association of ances-
try (outcome) and each tumor characteristic (main inde-
pendent variable), considering the following covariates:
age at recruitment, gender, ever smoked, current drinking,
and BMI. All statistical analyses were done using STATA
14.0 (STATA Corp., College Station, TX, USA).
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